Brian Sulpizio

Are you struggling with where to start when it comes to landing your first #MSL role? It's hard to even figure out where to start. Tom and Sarah's webinar on How To Land an MSL Role Without Experience is a great resource. Read this summary blog post (link is in the comments) of the key takeaways when approaching: 💥Transferrable skills 💥Automated resume rejections 💥Confidence issues (Yes! You do have what it takes to be an MSL!) #aspiringmsl #jobsearch #MSLs #medicalscienceliaison

7

1 Comment

Patient access barriers are shifting, along with regulations and changing payer strategies. Tomorrow, hear the results of our #MarketAccess survey as experts from MMIT and The Dedham Group discuss best practices for #pharma companies in this BioPharma Dive webinar: https://ow.ly/Bh1850RIZaM.

13

Learn 4 ways pharma is getting creative with physician engagement, from using real-time lab alerts to better tracking for pull-through messaging. https://ow.ly/IKqU50SJGmm

6

Did you know over half of payers anticipate more PBMs are likely to begin to pursue vertical integration, further expanding access to biosimilars? See this insight from our MMIT Rapid Event Primer analysts: https://ow.ly/P7Gb50TemVE.

18

READ NOW: NAVLIN Last Week in Review https://ow.ly/Itaa50SM8Mv This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world: Policy: Discover the latest obligations for manufacturers aiming to enter the European market, as clarified by the Hungarian presidency in the Council of the European Union’s recent deliberations. Pricing & Reimbursement: Learn why Germany’s Federal Joint Committee (G-BA) has temporarily suspended the benefit assessment for Janssen’s Carvykti in its new indication for treating relapsed and refractory multiple myeloma. HTA: Explore how France’s High Authority for Health (HAS) is paving the way for early access to Vertex’s groundbreaking CRISPR/Cas9 gene-edited therapy for severe sickle cell disease. Drug Approval: Get the latest updates from the EMA’s Human Medicines Committee (CHMP) on 14 new medicine approvals and 11 indication extensions in the EU. C&G Therapy: Find out why the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended public reimbursement for CSL Behring’s innovative gene therapy for hemophilia B. And more... #EURegulations #HealthcarePolicy #GeneTherapy #PharmaApprovals #GeneTherapy

6

Check out AscellaHealth’s Q2 Specialty & Rare Pipeline Digest featuring the latest updates on recent specialty drug approvals, upcoming reviews, CGT and biosimilar pipelines. If you haven’t already, make sure to subscribe today: https://lnkd.in/epMupw4w #specialtypharmacy #pharmaceuticals #raredisease #FollowAscellaHealth 

2

If you missed yesterday’s Reimbursement Considerations in Product Commercialization webinar, you can watch it now! Michael Anselmo, John Schmitt, Anne O'Brien, and Nicole Fitzpatrick, PhD discussed the critical need for a thoughtful market access plan and showed attendees how to develop a successful Reimbursement and Market Access strategy for their company. MCRA’s experts also shared tools that can be used for a successful commercialization strategy. Watch the Reimbursement Considerations in Product Commercialization webinar here: https://lnkd.in/eUx3A4HG #reimbursement #MedTech #medicaldevices #marketaccess #healthcareeconomics #healthcareindustry #medtechindustry #medtechinnovation #webinar #free #reimbursementstrategy #MCRA

20

1 Comment

🙌 New Podcast Alert. 🚨 This week featuring ALCOA Consulting, LLC talking about the state of the job market in 2024 and all things clinical operations. Tune in now 👍 https://lnkd.in/e4hgQMxi

3

1 Comment

Check out our biweekly blog series “What CITI Program is Reading.” This week's titles include: •FDA qualifies Apple Watch’s AFib history for use in clinical studies •HHS: Report Change Healthcare Breach; CMS Research Data Restriction Opposed •U.S. moves to reclassify cannabis as a lower risk drug See this week's complete list now. What have you been reading? Let us know in the comments. https://loom.ly/2RTTuZQ #AFib #ChangeHealthcare #Cannabis

6

BMS is poised to enter the Eosinophilic Esophagitis (EoE) market. Buried in the BMS Q2 2024 earnings call was news that company's eosinophilic esophagitis (EoE) treatment, cendakimab, successfully met Phase 3 clinical endpoints. Similar to already-approved, Dupixent, cendakimab is a biologic with subcutaneous injections every other week. Specifics on the data have yet to be released, this new agent could pose some competitive pressure for Dupixent in EoE. #gastroenterology #clinicaldata https://lnkd.in/g_2a2MWv

9

Before the next pandemic, the #ClinicalTrial world must have a robust response plan in place and preparations for its rapid rollout. Listen to the latest PPD podcast episode to better understand the factors that will impact the success of any pandemic preparedness plan: https://bit.ly/40oROz3

1

📢 Join us on December 12 at 1 PM (CT) for an Alluma webinar, “Understanding the PBM Regulatory Landscape: Key Updates and What’s Ahead.” 🚀 The Pharmacy Benefit Manager (PBM) landscape is evolving rapidly, with new regulations affecting transparency, pricing and patient access. 🔍 What You’ll Learn: - Key federal and state regulations shaping the PBM industry - Insights into the FTC’s ongoing inquiry into PBM practices - The latest on ERISA exemptions and their impact on health systems - A preview of upcoming 2025 legislative trends 🎤 Meet Our Panelists: Jim Berg - VP, Operations and Client Management Jon Glos - VP, Business Development Amber Larsen - Manager, Compliance Don’t miss this chance to stay ahead of the curve on PBM regulations and their impact on healthcare. 👉Register now to secure your spot! https://bit.ly/3V0vKrk #Alluma #PBM #HealthcareRegulations #Webinar #PharmacyBenefitManager

9

🚨 Last Call for Advantage Pricing! Don't Miss Out! Time is running out! The Advantage Pricing deadline for #thINcMedMeetings - the Pharmaceutical and Medical Meeting Planners’ Summit is approaching fast—be sure to register by November 15 to secure your spot! 🗓 Event Dates: December 2-3, 2024 📍 Location: Boston, MA https://lnkd.in/eYgGxF3j This year’s theme—Challenge the Status Quo: Embrace Innovation and Shift to a New Era of Medical Meetings—is all about pushing boundaries and redefining what’s possible in the pharmaceutical, medical, and healthcare meetings space. Medical meeting planners today face unparalleled challenges: from tighter budgets and contract complexities to audience engagement and the ongoing global economic pressures. This Summit is your opportunity to connect with industry leaders and peers, explore forward-thinking strategies, and develop tools to optimize and elevate every aspect of your events. Why attend? Transformative Insights: Learn to adopt new, sustainable approaches that maintain quality while reducing costs. Collaborative Networking: Build partnerships and gain insights from like-minded professionals. Innovative Solutions: Discover strategies to tackle challenges like contract negotiation, budgeting, and audience engagement head-on. Don’t miss your chance to be part of this transformative experience! Register by November 15 for Advantage Pricing and secure your place among top medical meeting professionals. 👉 Ready to lead the change? Register now! *** Act now to save $100. Use promo code "SM2024" when you register.* We have a limited number of $149 passes available for Corporate Meeting Planners, but they are going fast! Register by November 15 to save $100 - that's a two day ticket for $49! Use promo code "SM2024" when you register.* (To qualify, you must be a direct employee of a Healthcare, Life Sciences, Pharma, Medical Device, or Biotech Company.) **All registrations subject to review by the thINc team. Promo codes not applicable for Standard Rates. Discount codes are only applicable to NEW registrations. #thINcMedMeetings #MedMeetings #PharmaMeetings #MeetingProfs #EventProfs #meetingplanners #LifeSciences #eventplanner #b2bevents #PharmaMeetings #MedicalEvents #EventPlanning

1

Are you attending the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Rockville, MD? If so, make sure to stop by Booth #18 to see our teammates Lei Wang, Helena Fan, & Bill Emker. #Pharm #pharma #statistics #biostatistics #statistican #biostatistician #datascience

5

1 Comment

Find out if your #biopharma sales force is calling on the right HCPs at the proper frequency with our GAPPS® assessment, which statistically evaluates the #productivity and #efficiency of HCP targets & call plans.   #pharmaceuticals #biotechnology #medicaldevices #lifesciences #innovation #motivation #consulting #sales #compensation #strategy #business https://lnkd.in/gfb4epC

12

1 Comment